Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression.
Shapiro
R
R
University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pennsylvania, USA.
Jordan
M L
ML
Scantlebury
V P
VP
Vivas
C
C
Gritsch
H A
HA
McCauley
J
J
McQuitty
D
D
Randhawa
P
P
Irish
W
W
McMichael
J
J
Hakala
T R
TR
Simmons
R L
RL
Fung
J J
JJ
Starzl
T E
TE
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone; D016559:Tacrolimus